MTIIs were developed by the UK government in collaboration with the Association of the British Pharmaceutical Industry (ABPI), in collaboration with stakeholders such as the Health Research Authority and the Medical Research Council. In addition, there are separate model agreements for non-commercial research/investigation, collaborative research and primary procurement studies. Launched in February 2011, the Model Industry Collaborative Research Agreement (MICRA) aims to support cooperation in clinical research involving the pharmaceutical and biotechnology industries, universities and NHS organisations in the UK. „Scotland has been at the centre of negotiations on the development of the new model of the Clinical Trials Agreement (MCTA). Implementing a single UK agreement streamlines the research environment across the UK and improves our international competitiveness. The revised models for February 2018 of the Clinical Trial Agreement (mCTA) and the Clinical Research Organisation model Clinical Trial Agreement (CRO-mCTA) are designed to be used without modification for industry-sponsored studies of patients with NHS/HSC in hospitals across the UK health service. It is hoped that this updated agreement will be leveraged by NHS companies and research sites without modification, which will reduce the time it will take to complete clinical trials. The Clinical Trial Agreement for pharmaceutical and biopharmaceutical industry sponsored research in primary care (Primary Care mCTA) has been before a piece of research can start, sponsors and host institutions need have appropriate agreements have place. Considerable time and effort may be required to develop different versions of these agreements for different research scenarios. To simplify this process, UKCRC partners and stakeholders have developed a series of agreement models that can be used „from the bar“ without modification. „The work done with the commercial sector to revise this model agreement will be invaluable for Northern Ireland – health and social care trusts and commercial sponsors can quickly sign contracts for studies that allow patients to access innovative new research treatments sooner.“ „In Wales, together with our business and UK government colleagues, we have developed a model agreement that will make a significant contribution to improving the speed, ease and effectiveness of high-quality research for the benefit of patients. The collaborative approach recommends the systematic and unchanged application of the clinical trial agreement model, and we support its application.

The MCTA is a standard form contract that must be used unchanged by clinical trial proponents and NHS/HSC organizations. Previously, in accordance with the 2011 version, separate agreements were needed for each of the four nations, England, Scotland, Wales and Northern Ireland. The new model allows for the use of a single agreement across the UK and streamlines the process for companies wishing to conduct multi-site clinical trials. MICRA was developed by a working group led by the NIHR Office for Clinical Research Infrastructure (NOCRI) and the Medical Research Council. Representatives from industry, universities, the NHS and the Intellectual Property Office worked with legal opinions to develop a model agreement that could support all collaborative research scenarios. Organizations participating in the working group agreed on a statement of support in which they encouraged their use to streamline the collaborative research allocation process. The new version of the Model Clinical Trials Agreement (mCTA) will allow the use of a single model contract for commercial research and development in England, Scotland, Wales and Northern Ireland, resulting in the breakdown of unnecessary administrations to conduct the same study in the UK.